Liquid Biopsies | Clinical

Liquid Biopsy HIC Proteomic Testing May Aid in NSCLC Treatment Decision-Making

September 02, 2022

In an interview with Targeted Oncology, David Oubre, MD discussed the use of liquid biopsy to identify prognostic and predictive biomarkers in patients with non–small cell lung cancer. He also explained the results and implications of the INSIGHT study.

Novel Liquid Biopsy Performed Favorably Over Needle-Based Biopsies in HER2+ Breast Cancer

June 27, 2022

In patients with HER2-positive breast cancer, an investigational liquid biopsy was more favorable compared with needle biopsies, a study shows.

Roundtable Discussion: Participants Reflect on Sending Blood- Vs Tissue-Based Tests in NSCLC

July 26, 2021

During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer.

Novel Blood-Based Biopsy Shows High Accuracy in Detection of Lymph Node Metastasis in CRC Specimens

April 22, 2021

A novel liquid biopsy test for the detection of lymph node metastasis in individuals with high-risk submucosal colorectal carcinoma has been developed.

Liquid Biopsy NonInferior to Tissue for Detection of Targetable Mutations in Advanced NSCLC

February 01, 2021

Significantly more genomic alterations can be detected with the Guardant360 liquid biopsy assay when used prior to tissue testing, results of a prospective study recently showed.

Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays

November 20, 2020

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.

FoundationOne Liquid CDx Granted New and Expanded FDA Indications in Various Solid Tumors

October 28, 2020

The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.

FDA Approves Liquid Biopsy Companion Diagnostic for Multiple Indications

August 27, 2020

The FDA has granted approval to FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for all solid tumors with multiple companion diagnostic indications.

What’s Driving, and Blocking the Liquid Biopsy Evolution in Non–Small Cell Lung Cancer?

August 20, 2020

The application of liquid biopsies is becoming more common in the field of non–small cell lung cancer as the utility of liquid biopsies in the detection of key biomarkers continues to be confirmed through clinical trials.

Bladder EpiCheck Demonstrates Accuracy for Detection of Urothelial Carcinoma Recurrence

July 20, 2020

“Accurately identifying patients with high-grade UTUC is critical, as the disease progression can be deadly and the standard treatment – removal of ureter and kidney – leads to major morbidity."